Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe.
Enver AydilekGerald WulfFriedrich SchwarzVera Ulrike BacherMathias RummelOlga StiefelAndrea KerkhoffMarkus MaulhardtThomas MelchardtThomas PabstGeorg LenzEvgenii ShumilovPublished in: Cancer medicine (2024)
In summary, pirtobrutinib represented a safe and effective treatment option in a small real-world population.